ocriplasmin sold brand name jetrea recombinant protease activity fibronectin laminin components vitreoretinal interface used treatment symptomatic vitreomacular adhesion received fda approval october works dissolving proteins link vitreous macula resulting posterior detachment vitreous ocriplasmin injectable drug truncated form human serine protease plasmin protease plasmin still retains enzymatic ocriplasmin consists two polypeptide chains linked disulfide bonds additionally longer peptide chain four disulfide bonds ocriplasmin moderately stable injected due autolytic ocriplasmin degrade various structural proteins including laminin fibronectin localized vitreoretinal surface two proteins involved vitreoretinal attachment ocriplasmin currently studied clinical trials data indicate able induce posterior vitreous detachment vitreomacular adhesion thrombogenics manufacturer ocriplasmin encountered several problems trying get approval drug fda brought problem adverse side effects associated drug fda stated adverse effects may cause longterm harm conclusion could definitively several days later fda endorsed ocriplasmin still experimental drug advisory committee brought several safety issues committee ended voting additional studies may controversial considering drug underwent two part deal alcon thrombogenics received million exus rights ocriplasmin part millionplus deal thrombogenics received millionplus payment ocriplasmin gained approved europe union occurred march market ocriplasmin united states quarter million httpsenwikipediaorgwikiocriplasmin